This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-outlook: Archive
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 10.71% and 196.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
BRTXPositive Net Change SCPHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 0% and 34.44%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
XBIOPositive Net Change PRPHPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
U.S. Physical Therapy (USPH) Lags Q2 Earnings Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -9.88% and 3.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
USPHNegative Net Change PDCOPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
SpringBig Holdings, Inc. (SBIG) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
SpringBig Holdings, Inc. (SBIG) delivered earnings and revenue surprises of 0% and 2.77%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
SBIGPositive Net Change PLPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sutro Biopharma (STRO) delivered earnings and revenue surprises of 22.37% and 2.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
STROPositive Net Change ARQTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Beam Global (BEEM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Beam Global (BEEM) delivered earnings and revenue surprises of 30% and 9.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
BEEMNegative Net Change REEPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
QuickLogic (QUIK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
QuickLogic (QUIK) delivered earnings and revenue surprises of -600% and 8.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
QUIKNegative Net Change AVGOPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Xos, Inc. (XOS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xos (XOS) delivered earnings and revenue surprises of 36.60% and 16.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
XOSPositive Net Change PSNYNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Nu Holdings Ltd. (NU) Q2 Earnings Beat Estimates
by Zacks Equity Research
Nu (NU) delivered earnings and revenue surprises of 20% and 1.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
NUPositive Net Change BKKTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
The Oncology Institute, Inc. (TOI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
The Oncology Institute (TOI) delivered earnings and revenue surprises of -70% and 4.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
TOINegative Net Change PINCNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Asensus Surgical (ASXC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of -40% and 69.77%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ASXCPositive Net Change LFWDNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Duos Technologies Group, Inc. (DUOT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Duos Technologies Group, Inc. (DUOT) delivered earnings and revenue surprises of -38.71% and 7.86%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
DUOTNegative Net Change ALLTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Intrusion Inc. (INTZ) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intrusion (INTZ) delivered earnings and revenue surprises of 26.39% and 16.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
INTZNegative Net Change LTRXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 14.63% and 72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
VTGNPositive Net Change CYCCNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -2.13% and 8.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ZVRANegative Net Change VRCAPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Gritstone bio (GRTS) delivered earnings and revenue surprises of 38.46% and 66.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
GRTSNegative Net Change BOLTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Reeds (REED) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Reeds (REED) delivered earnings and revenue surprises of -193.33% and 3.52%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
REEDNegative Net Change BRFHNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fate Therapeutics (FATE) delivered earnings and revenue surprises of 29.79% and 361.94%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
FATEPositive Net Change CYTHPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Intellinetics, Inc. (INLX) Misses Q2 Earnings Estimates
by Zacks Equity Research
Intellinetics (INLX) delivered earnings and revenue surprises of -50% and 0.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
INLXNegative Net Change MEIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
SurgePays, Inc. (SURG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
SurgePays, Inc. (SURG) delivered earnings and revenue surprises of -288.24% and 67.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
SURGNegative Net Change IOTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Intapp (INTA) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Intapp (INTA) delivered earnings and revenue surprises of 25% and 2.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
INTAPositive Net Change CGNTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Arcadia Biosciences (RKDA) Q2 Earnings Miss Estimates
by Zacks Equity Research
Arcadia Biosciences (RKDA) delivered earnings and revenue surprises of -38.58% and 37.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
RKDAPositive Net Change ICLPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Snail, Inc. (SNAL) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Snail, Inc. (SNAL) delivered earnings and revenue surprises of -66.67% and 22.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
SNALNegative Net Change SLEPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
CuriosityStream Inc. (CURI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CuriosityStream (CURI) delivered earnings and revenue surprises of 20% and 0.77%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
CURIPositive Net Change AOUTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Durect (DRRX) delivered earnings and revenue surprises of 29.41% and 12.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
DRRXPositive Net Change COSMPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank